The biggest advancements in sickle cell research over the past decade are the arrival of genetic therapies that can switch fetal hemoglobin back on or add a working globin gene, a better understanding of why sickled cells stick to blood vessels, and wider use of older proven treatments such as hydroxyurea. For the first time, a potentially curative option exists for more than just the minority of patients with a matched sibling donor. This overview walks through what those advances are, how they work, and where the limits still lie.
Much of the progress rests on decades of basic science about hemoglobin S and the way it distorts red cells into a sickle shape. Better care has also changed the outlook for survival, which I discuss in more depth in a separate piece on the life span of sickle cell patients.
The Disease Research Is Trying to Fix
Sickle cell disease (SCD) is an inherited group of disorders caused by a single change in the HBB gene, which codes for the beta-globin chain of adult hemoglobin. At the sixth position of that chain, valine replaces glutamic acid. The resulting protein is called sickle hemoglobin, or HbS.
When HbS gives up its oxygen, the molecules link into long, stiff polymers. The red cell becomes rigid and sticky, blocks small vessels, and breaks apart early. Normal red cells live about 120 days; sickle cells often survive only 10 to 20 days. That combination of blockage and destruction drives painful vaso-occlusive crises, chronic hemolytic anemia, stroke, acute chest syndrome, and slow damage to the spleen, kidneys, and lungs.
The condition is autosomal recessive. People with one HbS gene and one normal gene have sickle cell trait, which is usually silent and offers some protection against severe malaria. That survival advantage explains why the gene is common in people with roots in sub-Saharan Africa, the Mediterranean, the Middle East, and India. For a full clinical picture, see our comprehensive guide to sickle cell disease.
Earlier, Better Diagnosis
Research has not only been about treatment. Universal newborn screening in many countries now picks up the disease within days of birth, using high-performance liquid chromatography (HPLC) or isoelectric focusing. Early diagnosis matters because babies can then start penicillin prophylaxis and vaccinations before the spleen stops working properly.
Hemoglobin electrophoresis still separates disease from trait, and DNA testing of the HBB gene confirms unusual results and supports prenatal and preimplantation testing. You can read more about the process in our article on the diagnosis of sickle cell disease. Screening children with transcranial Doppler ultrasound to spot high stroke risk is another research-driven advance that is now routine care.
Drug Therapies: From Hydroxyurea to Newer Agents
Hydroxyurea remains the backbone of disease-modifying treatment. It raises fetal hemoglobin (HbF), which does not polymerize with HbS, so cells sickle less. It reduces painful crises, acute chest syndrome, and transfusion needs, and guidelines now recommend offering it from infancy for the most common genotypes. In my practice, it is still the medication that makes the most everyday difference for most patients.
Several newer drugs arrived in the late 2010s, each aimed at a different step in the disease process. Not all have held up equally well.
| Treatment | How it works | Current status |
|---|---|---|
| Hydroxyurea | Increases fetal hemoglobin; lowers white cell count and cell stickiness | First-line, widely used in children and adults |
| L-glutamine | Reduces oxidative stress inside red cells | Approved in the US to reduce acute complications |
| Crizanlizumab | Antibody that blocks P-selectin, a vessel-wall adhesion molecule | Benefit questioned by later studies; authorization withdrawn in some regions |
| Voxelotor | Holds hemoglobin in its oxygen-bound form to prevent polymerization | Withdrawn from the market by its manufacturer in 2024 over safety concerns |
| Chronic transfusion | Dilutes HbS with normal donor cells | Standard for stroke prevention in high-risk children |
The voxelotor story is a useful lesson. A drug that improved hemoglobin levels did not automatically translate into fewer crises or better survival, which is why regulators now ask for clinical outcomes, not just lab improvements.
Gene Therapy and Gene Editing: The Major Breakthrough
The most striking advancement in sickle cell research is the approval of genetic therapies. In late 2023, US regulators approved two approaches for patients aged 12 and older with recurrent crises.
Gene editing to restore fetal hemoglobin
One therapy uses CRISPR/Cas9 to disrupt an enhancer of the BCL11A gene in the patient’s own blood stem cells. BCL11A normally switches off fetal hemoglobin after infancy. Silencing it lets the new red cells make high levels of HbF, mimicking a naturally protective condition called hereditary persistence of fetal hemoglobin.
Gene addition with a viral vector
The other therapy uses a lentiviral vector to insert a modified beta-globin gene that resists sickling. The corrected stem cells then produce red cells carrying a mixture of normal-acting and sickle hemoglobin.
What the process involves
Both require collecting stem cells, modifying them in a lab, and giving high-dose chemotherapy (busulfan) to clear space in the marrow before reinfusion. That conditioning carries real risks, including infertility and a hospital stay of several weeks. Cost and access remain major barriers, especially in the regions where the disease is most common.
Stem Cell Transplant and Adhesion Research
Allogeneic stem cell transplantation from a matched sibling has been curative for many years, but most patients lack such a donor. Research into haploidentical transplants, using a half-matched family member, has widened the donor pool, and outcomes continue to improve at experienced centers.
Laboratory work has also shown that sickling is only part of the story. Sickle cells, white cells, and platelets stick to the vessel lining through molecules such as P-selectin, and chronic inflammation and oxidative stress keep that process going. Understanding normal erythrocyte function has helped researchers see which of these pathways might be targeted next. Base editing and prime editing, which change single DNA letters without cutting both strands, are being studied as ways to correct the mutation directly.
Key Takeaways
- Sickle cell disease comes from one amino acid change in beta-globin that makes hemoglobin polymerize when oxygen is low.
- Newborn screening, stroke screening, and hydroxyurea remain the proven foundations of care.
- Some newer drugs have been scaled back, which shows why clinical outcomes matter more than lab numbers.
- Gene editing and gene addition therapies now offer a possible one-time treatment for selected patients, but they are intensive and expensive.
- Transplant options have broadened with half-matched donors.
For a broader look at the condition and related topics, visit our sickle cell guide.
Frequently Asked Questions
Is there a cure for sickle cell disease now?
A stem cell transplant can cure the disease, and the newer gene therapies may offer a functional cure for eligible patients. Both involve intensive chemotherapy and are not suitable for everyone. For most people, long-term management with hydroxyurea and preventive care is still the mainstay.
Who is eligible for gene therapy?
Current approvals cover people aged 12 and older with frequent vaso-occlusive crises. A specialist center will also look at organ function, fertility wishes, and whether the patient can tolerate conditioning chemotherapy. Availability varies a great deal between countries.
Does hydroxyurea still matter now that gene therapy exists?
Yes. Hydroxyurea is oral, widely available, and has decades of safety experience. It reduces crises and hospital admissions for most patients, and many will never need or be able to access a genetic therapy.
Can people with sickle cell trait benefit from this research?
People with trait usually have no symptoms and do not need treatment. The research still matters to them for family planning, since two carriers have a one-in-four chance with each pregnancy of having a child with the disease.
Why was voxelotor withdrawn?
Its manufacturer withdrew it in 2024 after later data raised safety concerns, including more deaths and crises in some study groups. Patients who were taking it should discuss alternatives with their hematologist rather than stopping any medication on their own.
